Antithrombin and protein C in systemic inflammatory response syndrome

Asian Cardiovascular and Thoracic Annals

Volumn 15, Issue 1, 2007, Pages 39-44

  Massad, Islam ^b   Abu Ali, Hamdi ^b   Biron Andreani, Christine ^a   Picot, Marie Christine ^a   Trinh Duc, Philippe ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b JORDAN UNIVERSITY HOSPITAL   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; PROTEIN C;

ADULT; AGED; ANTITHROMBIN DEFICIENCY; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HIGH RISK PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; PREDICTION; PREOPERATIVE EVALUATION; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN C DEFICIENCY; RISK ASSESSMENT; SCORING SYSTEM; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TEMPERATURE MEASUREMENT;

EID: 33847787304     PISSN: 02184923     EISSN: None     Source Type: Journal    
DOI: 10.1177/021849230701500109     Document Type: Article

References (20)

1. Kollef MH, Wragge T, Pasque C. Determinants of mortality and multiorgan dysfunction in cardiac surgery patients requiring prolonged mechanical ventilation. Chest 1995;107:1395-401.
2. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery. Implications for the anesthesiologist. Anesthesiology 2002;97:215-52.
3. Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications [Review]. Semin Thromb Hemost 1998;24:27-32.
4. Esmon C. The protein C pathway [Review]. Crit Care Med 2000;28(Suppl):S44-8.
5. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardio-thorac Surg 1999;16:9-13.
6. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
7. Matthai WH Jr, Kurnik PB, Groh WC, Untereker WJ, Siegel JE. Antithrombin activity during the period of percutaneous coronary revascularization. J Am Coll Cardiol 1999;33:1248-56.
8. Cremer J, Martin M, Redl H, Bahrami S, Abraham C, Graeter T, et al. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996;61:1714-20.
9. Hensel M, Volk T, Docke WD, Kern F, Tschirna D, Egerer K, et al. Hyperprocalcitonemia in patients with noninfectious SIRS and pulmonary dysfunction associated with cardiopulmonary bypass. Anesthesiology 1998;89:93-104.
10. Oudemans-van Straaten HM, Jansen PG, Hoek FJ, van Deventer SJ, Sturk A, Stoutenbeek CP, et al. Intestinal permeability, circulating endotoxin, and postoperative systemic responses in cardiac surgery patients. J Cardiothorac Vasc Anesth 1996; 10:187-94.
11. Myles P, Buckland M, Cannon G, Bujor M, Anderson J, Salamonsen B, et al. The association among gastric mucosal pH, endotoxemia, and low systemic resistance after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1996; 10:195-200.
12. Neuhof C, Wendling J, Dapper F, Bauer J, Zickmann B, Jochum M, et al. Endotoxemia and cytokine generation in cardiac surgery in relation to flow mode and duration of cardiopulmonary bypass. Shock 2001;16(Suppl 1):39-43.
13. Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardio-thorac Surg 2002;21:232-44.
14. Whitten CW, Hill GE, Ivy R, Greilich PE, Lipton JM. Does the duration of cardiopulmonary bypass or aortic cross-clamp, in the absence of blood and/or blood product administration, influence the IL-6 response to cardiac surgery? Anesth Analg 1998;86:28-33.
15. Sakao Y, Nakahara Y, Carr FK, Miller EJ. Hypothermia augments polymorphonuclear leukocyte degranulation and interleukin-8 production from human umbilical vein endothelial cells and increases lipopolysaccharides-induced polymorphonuclear leukocyte-endothelial cell interaction when flowed by normothermia. J Cardiothorac Vasc Anesth 2002;16:561-6.
16. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference [Review]. Crit Care Med 2003;31:1250-6.
17. Drabe N, Zund G, Grunenfelder J, Sprenger M, Hoerstrup SP, Bestmann L, et al. Genetic predisposition in patients undergoing cardiopulmonary bypass surgery is associated with an increase of inflammatory cytokines. Eur J Cardio-thorac Surg 2001;20:609-13.
18. Schroeder S, Borger N, Wrigge H, Welz A, Putensen C, Hoeft A, et al. A tumor necrosis factor gene polymorphism influences the inflammatory response after cardiac operation. Ann Thorac Surg 2003;75:534-7.
19. Boeken U, Feindt P, Zimmermann N, Kalweit G, Petzold T, Gams E. Increased preoperative C-reactive protein (CRP)-values without signs of infection and complicated course after cardiopulmonary bypass (CPB)-operations. Eur J Cardio-thorac Surg 1998;13:541-5.
20. Woodward M, Rumley A, Lowe GD, Tunstall-Pedoe H. C-reactive protein: associations with haematological variables, cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 2003;122:135-41.